Topic: combination therapy
A combination of Novartis' Farydak and Incuron's experimental CBL0137 made neuroblastoma disappear In mice.
Nektar Therapeutics poached Genentech immunotherapy leader Wei Lin to head up its oncology program and serve as VP of clinical development.
A phosphor-binding site on aberrantly spliced BRAF V600E could become a new target against drug-resistant melanoma.
Scientists at Vanderbilt University found that a glutaminase inhibitor improved the anticancer activity of CAR-T cells.
A bottleneck of immunotherapy combination trials has put the field’s advancement on hiatus as researchers and drugmakers wait for the next discovery.
SpringWorks Therapeutics named its first CEO and unveiled a partnership with BeiGene around a combination therapy for RAS-mutated cancers.
Researchers used the gene editing system CRISPR-Cas9 to discover a signature of resistance to BRAF inhibitors in melanoma.
Arcus Biosciences and Infinity Pharmaceuticals plan to mix their lead programs in triple-combination immunotherapy trials in breast and ovarian cancer.
Early data from Zymeworks showed its lead bispecific antibody hit an overall response rate of 36%, as a single agent for a variety of HER2+ cancers.
Syndax’s entinostat-Keytruda combination may have posted small gains in NSCLC, but an enrichment biomarker could predict increased clinical benefit.